Metagenomi Restructures, Prioritizes Hemophilia A Program

Metagenomi, a gene editing company, announced a strategic overhaul, reducing workforce by 25% and changing leadership. Doctor Jian Irish becomes CEO, Brian Thomas remains on the Board, and Doctor Willard Dere becomes Board Chair. The company is prioritizing its hemophilia A program, MGX-zero-zero-one, with promising preclinical data showing curative factor eight activity in non-human primates. Metagenomi expects to hold a pre-IND meeting for this program in Q4 2025 and submit for clinical trials in Q4 2026. The company reported $184.1 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with revised financial strategy extending cash reserves into Q4 2027. R&D expenses decreased to $25.3 million from $26.3 million in Q3 2024, and G&A expenses fell to $6.2 million from $7.6 million year-over-year.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.